- Home
- ASB vs RYTM Comparison
ASB vs RYTM Comparison
Compare ASB & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASB
- RYTM
- Stock Information
- Founded
- ASB 1861
- RYTM 2008
- Country
- ASB United States
- RYTM United States
- Employees
- ASB N/A
- RYTM N/A
- Industry
- ASB Major Banks
- RYTM Biotechnology: Pharmaceutical Preparations
- Sector
- ASB Finance
- RYTM Health Care
- Exchange
- ASB Nasdaq
- RYTM Nasdaq
- Market Cap
- ASB 3.4B
- RYTM 3.8B
- IPO Year
- ASB N/A
- RYTM 2017
- Fundamental
- Price
- ASB $23.16
- RYTM $61.33
- Analyst Decision
- ASB Hold
- RYTM Strong Buy
- Analyst Count
- ASB 11
- RYTM 12
- Target Price
- ASB $26.27
- RYTM $76.75
- AVG Volume (30 Days)
- ASB 1.1M
- RYTM 632.6K
- Earning Date
- ASB 07-24-2025
- RYTM 05-07-2025
- Dividend Yield
- ASB 3.97%
- RYTM N/A
- EPS Growth
- ASB N/A
- RYTM N/A
- EPS
- ASB 0.83
- RYTM N/A
- Revenue
- ASB $985,729,000.00
- RYTM $136,863,000.00
- Revenue This Year
- ASB $54.69
- RYTM $37.88
- Revenue Next Year
- ASB $5.77
- RYTM $72.84
- P/E Ratio
- ASB $28.01
- RYTM N/A
- Revenue Growth
- ASB N/A
- RYTM 48.88
- 52 Week Low
- ASB $18.32
- RYTM $35.35
- 52 Week High
- ASB $28.18
- RYTM $68.58
- Technical
- Relative Strength Index (RSI)
- ASB 51.50
- RYTM 51.78
- Support Level
- ASB $22.40
- RYTM $58.72
- Resistance Level
- ASB $23.57
- RYTM $63.24
- Average True Range (ATR)
- ASB 0.44
- RYTM 2.43
- MACD
- ASB -0.15
- RYTM -0.15
- Stochastic Oscillator
- ASB 31.93
- RYTM 65.51
About ASB Associated Banc-Corp
Associated Banc-Corp is a bank holding company. The company through its subsidiaries provides a broad array of banking and nonbanking products and services to individuals and businesses. The company operates in three reportable segments; Corporate and Commercial Specialty; Community, Consumer, and Business; and Risk Management and Shared Services. The majority of its revenue is derived from the Corporate and Commercial Specialty and Community, Consumer, and Business segments.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.